Our article after ten years: Intrathecal midazolam as supplementary analgesia for chronic lumbar pain – 15 years’experience

Czech version

Authors: J. Procházka ¹; A. Hejčl ²; L. Procházková ³
Authors‘ workplace: Centrum léčby chronické bolesti při Klinice anesteziologie, perioperační a intenzivní medicíny Univerzity J. E. Purkyně, Krajská zdravotní, a. s., Masarykova nemocnice o. z., Ústí nad Labem ¹; Neurochirurgická klinika Univerzity J. E. Purkyně, Krajská zdravotní, a. s., Masarykova nemocnice o. z., Ústí nad Labem ²; Oční klinika Univerzity J. E. Purkyně, Krajská zdravotní, a. s., Masarykova nemocnice o. z., Ústí nad Labem ³
Published in: Anest. intenziv. Med., 32, 2021, č. 2, s. 94-98
Category: Review Articles

Overview

Ten years ago, our experiences with intrathecal midazolam in patients suffering with chronic low back pain were published in Pain Medicine. This review article provides a critical assessment of our results and further development of this method as seen from a distance of one decade.

Keywords:

spinal analgesia – midazolam – chronic low back pain – failed back surgery syndrome – off‑ label therapy

Sources

1. Procházka J, Hejčl A, Procházková L. Intrathecal midazolam as supplementary analgesia for chronic lumbar pain – 15 years’experience. Pain Medicine 2011; 12: 1309–1315.

2. Velentine JMJ, Lyons G, Bellamy MC. The effect of intrathecal midazolam on post‑operative pain. Eur J Anaesthesiol 1996; 13(6): 589–593.

3. Prakash S, Joshi N, Gogia AR, Prakash S, Singh R. Analgesic efficacy of two doses intrathecal midazolam with bupivacaine in patients undergoing cesarean delivery. Reg Anesth Pain Med 2006; 31(3): 221–226.

4. Shah FR, Halbe AR, Panchal ID, Goodchild CS. Improvement in postopereative pain relief by the addition of midazolam to an intrathecal injection of buprenorphine and bupivacaine. Eur J Anesthesiol 2003; 20(11): 904–910.

5. Bharti N, Madan R, Mohanty PR, Kaul HL. Intrathecal midazolam added to bupivacaine improves duration and quality of spinal anesthesia. Acta Anaesthesiol Scand 2003; 47(9): 1101–1105.

6. Duncan MA, Savage J, Tucker APOD. Prospective audit comparing intrathecal analgesia (incorporating midazolam) with epidural and intravenous analgesia after major open abdominal surgery. Anaesth Intensive Care 2007; 35(4): 558–562.

7. Yegin A, Sanli S, Dosemeci L, Kayacan L, Akbas M, Karsli B. The analgesic and sedative effect of midazolam in perianal surgery. Eur J Anesthesiol 2004; 21(8): 658–662.

8. Borg PAJ, Krijnen HJ. Long‑term intrathecal administration of midazolam and clonidine. Clin J Pain 1996; 12(1): 63–68.

9. Nishiyama T, Yokoyama T, Hanaoka K. Midazolam improves postoperative epidural analgesia with continuous infusion of local anaesthetics. Can J Anaesth 1998; 45(6): 551–555.

10. Naguib M, El Gammal M, Elhattab YS, Seraj M. Midazolam for caudal analgesia for childern: comparison with caudal bupivacaine. Can J Anaesth 1995; 42(9): 758–764.

11. Serrao JM, Marks RL, Morley SJ, Goodchild CS. Intrathecal midazolam for the treatment of chronic mechanical low back pain: A controlled comparison with epidural steroids in a pilot study. Pain 1992; 48(1): 5–12.

12. Procházka J. Descendentní GABA‑ergní inhibice v léčbě bolesti – je něco nového? Naše 20leté zkušenosti. Bolest 2017; 20(2): 80–88.

13. Deer TR, Pope JE, Hayek SM, Bux A, Buchser E, Eldabe S, et al. The Polyanalgesic Consensus Conference (PACC): Recommendations on intrathecal drug infusion systems best practices and guidelines. Neuromodulation 2017; 20(2): 96–132.

14. Saulino MF, Patel T, Fisher SP. The application of falure modes and effects analysis methodology to intrathecal drug delivery for pain management. Neuromodulation 2017; 20: 177–186.

15. Yaksh TL, Fisher CJ, Hockman TM, Wiese AJ. Current and future issues in the development of spinal agents for the management of pain. Curr Neuropharmacol 2017; 15(2): 232–259.

16. McDowell GC, Pope JE. Intrathecal ziconotide: dosing and administration strategies in patients with refraktory chronic pain. Neromodulation 2016; 19: 522–532.

17. Pope JE, Deer TR, Bruel BM, Falowski S. Clinical uses of intrathecal therapy and its placement in the pain care algorithm. Pain Practice 2016; 16(8): 1092–1106.

18. Emami A, Tepper J, Short B, Yaksh TL, Bendele AM, Ramani T, et al. Toxicology evaluation of drugs administered via uncommon routes: intranasal, intraocular, intrathecal/intraspinal and intra‑articular. Int J Toxicology 2017; 37(1): 4–27.

19. Wilson G, Rupp C, Wilson WW. The dangers of intrathecal medication. JAMA 1949 Jul 30; 40(13): 1076–1079.

20. Hodgson PS, Neal JM, Pollock JE, Liu SS. The neurotoxicity of drugs given intrathecally (spinal). Anesth Analg 1999; 88(4): 797–809.

21. Bottros MM, Christo PJ. Current perspectives on intrathecal drug delivery. J Pain Res 2014; 7: 615–626.

22. Khoshfetrat M, Davarpanah S, Keykha A. Egffacacy of intrathecal midazolam on enhancing analgesic effect of fentanyl in patients undergoing lower limb surgery. Biomed Res Ther 2018; 5(10): 2726–2732.

23. Abdollahpour A, Azadi R, Bandari R, Mirmohammadkhani M. Effects of adding midazolam and sufentanil to intrathecal bupivacaine on analgesia quality and postoperative complications in elective cesarean section. Anesth Pain Med 2015; 5(4): e23565.

24. Boules ML, Botros JM. Comparative study between the effect of intrathecal midazolam versus intrathecal midazolam plus magnesium sulphate on the efficacy and duration of analgesia in patients undergoing cesarean section. Ain‑Shams J Anesthesiol 2015; 08: 70–75.

25. Dodawad R, Sumalatha GB, Pandarpurkar S, Jajee P. Intrathecal midazolam as an adjuvant in pregnancy‑ induced hypertensive patients undergoing an elective caesarean section: a clinical comparative study. Anesth Pain Med 2016; 6(5): e38550.

26. Francis C, Vitalis M, Thikra S. A randomised controlled trial comparing the effect of adjuvant intrathecal 2 mg midazolam to 20 micrograms fentanyl on postoperative pain for patients undergoing lower limb orthopaedic surgery under spinal anaesthesia. Afri Health Sci 2016; 16(1): 282–291.

27. Kishnani KL, Gupta A, Bansal A. Comparison of intrathecal bupivacaine and bupivacaine plus midazolam in spinal analgesia. Paripex Ind J Res 2019; 8(6): 19–22.

28. Schultz DM, Abd‑Elsayed A, Calodney A, Stromberg K, Weaver T, Spencer RJ. Targeted drug delivery for chronic nonmalignant pain: Longitudinal data from the product surveillance registry. Neuromodulation 2021; doi: 10.1111/ner.13353

29. Neuromodulation Product Performance – Summary of Data from the Medtronic Post‑market Registry. [on‑line]. Dostupné z: https://www.medtronic.com/us‑en/ healthcare‑professionals/ products/product‑performance/ neuromodulation‑product‑performance. html

30. Procházka J. Má off‑ label léčba význam pro rozvoj léčebných postupů? Bolest 2005; 8: 21–26.

31. Herold I. Neregistrované (off‑ label) indikace registrovaných farmak v regionální anestezii. Regionální anestezie 1999; 4: 27–30.

32. Procházka J. Intrathecal midazolam as an analgesic in chronic back pain. In: Duncan LT. Advances in Health and Disease. Nova Science Publishers, Inc., New York, 2019; 9: 85–104. (ISBN 978-1-53614-793-3 eBook).